Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04075435 · ClinicalTrials.gov registry record · Early Phase 1
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
A Early Phase 1 study of Anxiety and Alzheimer Disease, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04075435 is a Early Phase 1 study of Anxiety and Alzheimer Disease that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 12 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04075435, a Early Phase 1 study of Anxiety and Alzheimer Disease, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).
Conditions Studied
Interventions
- DRUG high CBD/low THC sublingual solution
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2026-01-16 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04075435
The ClinicalTrials.gov registry entry for NCT04075435 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (97% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which high CBD/low THC sublingual solution is the first listed.
NCT04075435 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04075435 about?
NCT04075435 is a clinical study titled "Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia". This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).
What is the current status of trial NCT04075435?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2021-01-11. Estimated completion is 2026-01-16.
What conditions does trial NCT04075435 study?
This clinical trial studies the following conditions: Anxiety, Alzheimer Disease, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease.
What interventions are being tested in trial NCT04075435?
The interventions under investigation include: high CBD/low THC sublingual solution (DRUG).
Who is sponsoring clinical trial NCT04075435?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04075435 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sleep, Dreaming, and Virtual Reality for Mental Health
RECRUITING · Early Phase 1
-
Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Probiotics for Quality of Life in Autism Spectrum Disorders
COMPLETED · Early Phase 1
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.